Newsroom | 22095 results
Sorted by: Latest
-
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast prese...
-
ImmunoPrecise annonce une avancée majeure basée sur l'IA dans la découverte d'un vaccin universel contre la dengue
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA), un chef de file de la biothérapie optimisée par l'IA, annonce la découverte d'un épitope hautement conservé sur les quatre sérotypes du virus de la dengue en utilisant sa plateforme propriétaire LENSai™ optimisée par sa technologie brevetée HYFT®. Cette découverte, réalisée à l'aide de plusieurs analyses exclusives basées sur HYFT, identifie une partie du virus (un épitope) qui est restée non mutée sur les quatre...
-
MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics
ANDOVER, Mass. & HAIFA, Israel--(BUSINESS WIRE)--100,000 patients have now been tested with MeMed BV, a host-response diagnostic that accurately distinguishes between bacterial and viral infections....
-
Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care
GOLDEN, Colo.--(BUSINESS WIRE)--Publication in Vaccines highlights that when compared to the SoC in an RI study, Tropis demonstrated increased coverage, cost savings and preference....
-
Kalderos’ Industry-Leading Push for Transparency in 340B Drug Pricing Program Validated by Federal Court Ruling; Continued Delay in Implementation Hampers Meaningful Progress
CHICAGO--(BUSINESS WIRE)--Despite the U.S. District Court for the District of Columbia recently asserting that the 340B statute “explicitly contemplates” rebate models, those seeking to improve the 340B program’s transparency and ensure its efficacy remain in a holding pattern. This week, in response to years of efforts led by Kalderos and other 340B program stakeholders to implement a rebate model in the federal drug pricing program, the U.S. Department of Health and Human Services (HHS) submi...
-
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowi...
-
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease...
-
Riassunto: Fujirebio annuncia una collaborazione strategica con Stanford Medicine per promuovere la ricerca sulle malattie infettive
TOKYO & SUNNYVALE, Calif.--(BUSINESS WIRE)--Fujirebio, un importante innovatore nella diagnostica in-vitro, oggi ha annunciato una collaborazione con Stanford Medicine (Sede: Palo Alto, California, USA) per promuovere la ricerca e l'innovazione nel settore delle analisi sulle malattie infettive. Questa collaborazione mira ad accelerare l'adozione di test immunologici ultra sensibili che incorporano una tecnologia che conta le singole molecole sviluppata da Fluxus, Inc., un'azienda della Silicon...
-
Fujirebio anuncia una colaboración estratégica con Stanford Medicine para avanzar en la investigación de enfermedades infecciosas
TOKIO & SUNNYVALE, California--(BUSINESS WIRE)--Fujirebio, empresa innovadora líder en diagnóstico in-vitro, acaba de anunciar una colaboración con Stanford Medicine (Palo Alto, California, EE. UU.) para impulsar la investigación y la innovación en el campo de las pruebas de enfermedades infecciosas. Esta colaboración tiene por objetivo acelerar la adopción de inmunoensayos ultrasensibles que incorporen la tecnología de recuento de moléculas individuales desarrollada por Fluxus, Inc., filial de...
-
Fujirebio annonce une collaboration stratégique avec Stanford Medicine visant à faire progresser la recherche sur les maladies infectieuses
TOKYO & SUNNYVALE, Californie--(BUSINESS WIRE)--Fujirebio, un innovateur de premier plan dans le domaine du diagnostic in vitro, a annoncé aujourd’hui une collaboration avec Stanford Medicine (situé à Palo Alto, Californie, États-Unis) afin de faire progresser la recherche et l’innovation dans le domaine des tests de dépistage des maladies infectieuses. Cette collaboration vise à accélérer l’adoption d’immunoessais ultrasensibles intégrant la technologie de comptage de molécules individuelles d...
